Letters to the Editor

Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030
Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030
Department of Leukemia, MD Anderson Cancer Center, Houston, Texas 77030
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110
Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri 63110
Albert Einstein College of Medicine, Bronx, New York 10461
Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110; A2 Biotherapeutics, Agoura Hills, California 91301 (work completed while at Washington University)
Haematologica Early view Apr 11, 2024 https://doi.org/10.3324/haematol.2022.281396